The FDA approves vutrisiran (Amvuttra) as the first RNAi therapeutic to reduce cardiovascular events and mortality in adults with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
Researchers discover erythropoietin released after blood donation selectively favors specific DNMT3A mutations in stem cells, revealing how frequent donation creates evolutionary pressure that differs from cancer-associated pathways.